JP6791854B2 - 組織適用におけるlgr4、lgr5およびlgr6発現上皮幹細胞を用いた最小限分極機能性細胞微細凝集塊単位の開発および使用のための方法 - Google Patents
組織適用におけるlgr4、lgr5およびlgr6発現上皮幹細胞を用いた最小限分極機能性細胞微細凝集塊単位の開発および使用のための方法 Download PDFInfo
- Publication number
- JP6791854B2 JP6791854B2 JP2017530217A JP2017530217A JP6791854B2 JP 6791854 B2 JP6791854 B2 JP 6791854B2 JP 2017530217 A JP2017530217 A JP 2017530217A JP 2017530217 A JP2017530217 A JP 2017530217A JP 6791854 B2 JP6791854 B2 JP 6791854B2
- Authority
- JP
- Japan
- Prior art keywords
- tissue
- lgr6
- lgr
- cells
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004027 cell Anatomy 0.000 title claims description 162
- 102100024140 Leucine-rich repeat-containing G-protein coupled receptor 6 Human genes 0.000 title claims description 134
- 101000981765 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 6 Proteins 0.000 title claims description 133
- 210000000130 stem cell Anatomy 0.000 title claims description 97
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 title claims description 50
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 title claims description 47
- 238000000034 method Methods 0.000 title claims description 38
- 102100031035 Leucine-rich repeat-containing G-protein coupled receptor 4 Human genes 0.000 title claims description 28
- 101001063463 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 4 Proteins 0.000 title claims description 4
- 238000011161 development Methods 0.000 title description 15
- 208000027418 Wounds and injury Diseases 0.000 claims description 190
- 210000001519 tissue Anatomy 0.000 claims description 158
- 206010052428 Wound Diseases 0.000 claims description 155
- 239000000203 mixture Substances 0.000 claims description 45
- 230000035876 healing Effects 0.000 claims description 42
- 210000003780 hair follicle Anatomy 0.000 claims description 36
- 239000011159 matrix material Substances 0.000 claims description 34
- 210000003491 skin Anatomy 0.000 claims description 31
- 239000000758 substrate Substances 0.000 claims description 26
- 238000002054 transplantation Methods 0.000 claims description 19
- 210000004207 dermis Anatomy 0.000 claims description 17
- 108010035532 Collagen Proteins 0.000 claims description 15
- 102000008186 Collagen Human genes 0.000 claims description 15
- 229920001436 collagen Polymers 0.000 claims description 15
- 239000000835 fiber Substances 0.000 claims description 15
- 210000002615 epidermis Anatomy 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 12
- 239000003102 growth factor Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 108050003627 Wnt Proteins 0.000 claims description 9
- 102000013814 Wnt Human genes 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 8
- 229940012952 fibrinogen Drugs 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 102000008946 Fibrinogen Human genes 0.000 claims description 6
- 108010049003 Fibrinogen Proteins 0.000 claims description 6
- 229930182555 Penicillin Natural products 0.000 claims description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 6
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 6
- 239000003429 antifungal agent Substances 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 229940049954 penicillin Drugs 0.000 claims description 6
- 229960005322 streptomycin Drugs 0.000 claims description 6
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 5
- 102000037126 Leucine-rich repeat-containing G-protein-coupled receptors Human genes 0.000 claims description 5
- 108091006332 Leucine-rich repeat-containing G-protein-coupled receptors Proteins 0.000 claims description 5
- 229960003942 amphotericin b Drugs 0.000 claims description 5
- 229940121375 antifungal agent Drugs 0.000 claims description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000001617 migratory effect Effects 0.000 claims description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 3
- 108700004203 eye-derived growth factor Proteins 0.000 claims description 3
- 230000001483 mobilizing effect Effects 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 230000009870 specific binding Effects 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 2
- 230000008472 epithelial growth Effects 0.000 claims 1
- 229940106780 human fibrinogen Drugs 0.000 claims 1
- 230000014509 gene expression Effects 0.000 description 55
- 210000000988 bone and bone Anatomy 0.000 description 47
- 210000002304 esc Anatomy 0.000 description 39
- 208000014674 injury Diseases 0.000 description 38
- 239000002609 medium Substances 0.000 description 38
- 230000006378 damage Effects 0.000 description 36
- 102100021420 Defensin-5 Human genes 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 34
- 101710174259 Leucine-rich repeat-containing G-protein coupled receptor 4 Proteins 0.000 description 24
- 230000001580 bacterial effect Effects 0.000 description 24
- 230000001413 cellular effect Effects 0.000 description 22
- 230000010287 polarization Effects 0.000 description 22
- 238000011002 quantification Methods 0.000 description 22
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 22
- 229960004306 sulfadiazine Drugs 0.000 description 22
- 230000005012 migration Effects 0.000 description 21
- 238000013508 migration Methods 0.000 description 21
- 230000006698 induction Effects 0.000 description 18
- 230000029663 wound healing Effects 0.000 description 18
- 230000008929 regeneration Effects 0.000 description 16
- 238000011069 regeneration method Methods 0.000 description 16
- 102100022464 5'-nucleotidase Human genes 0.000 description 14
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 14
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 14
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 14
- 230000018109 developmental process Effects 0.000 description 14
- 210000003205 muscle Anatomy 0.000 description 14
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 12
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 12
- 238000010899 nucleation Methods 0.000 description 12
- 230000004156 Wnt signaling pathway Effects 0.000 description 11
- 230000010261 cell growth Effects 0.000 description 11
- 238000003384 imaging method Methods 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 10
- 210000000442 hair follicle cell Anatomy 0.000 description 10
- 230000003779 hair growth Effects 0.000 description 10
- 239000011800 void material Substances 0.000 description 10
- 101001041589 Homo sapiens Defensin-5 Proteins 0.000 description 9
- 230000029918 bioluminescence Effects 0.000 description 9
- 238000005415 bioluminescence Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000003925 fat Substances 0.000 description 9
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 8
- 238000012790 confirmation Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000004209 hair Anatomy 0.000 description 8
- 102000048466 human DEFA5 Human genes 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000001000 micrograph Methods 0.000 description 8
- 206010033675 panniculitis Diseases 0.000 description 8
- 238000009331 sowing Methods 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 210000004304 subcutaneous tissue Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000017423 tissue regeneration Effects 0.000 description 8
- 230000035899 viability Effects 0.000 description 8
- 108020004465 16S ribosomal RNA Proteins 0.000 description 7
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 7
- 238000004624 confocal microscopy Methods 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 210000004907 gland Anatomy 0.000 description 7
- 239000007943 implant Substances 0.000 description 7
- 210000004901 leucine-rich repeat Anatomy 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 230000008093 supporting effect Effects 0.000 description 7
- 210000002435 tendon Anatomy 0.000 description 7
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 6
- 102000004379 Adrenomedullin Human genes 0.000 description 6
- 101800004616 Adrenomedullin Proteins 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 6
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 238000002659 cell therapy Methods 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000012292 cell migration Effects 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 238000011194 good manufacturing practice Methods 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 5
- 230000001172 regenerating effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000004003 subcutaneous fat Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108091006027 G proteins Proteins 0.000 description 4
- 102000030782 GTP binding Human genes 0.000 description 4
- 108091000058 GTP-Binding Proteins 0.000 description 4
- 102100033511 Keratin, type I cytoskeletal 17 Human genes 0.000 description 4
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 210000003981 ectoderm Anatomy 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000007634 remodeling Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 3
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 3
- 102000005698 Frizzled receptors Human genes 0.000 description 3
- 108010045438 Frizzled receptors Proteins 0.000 description 3
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 description 3
- 101000825954 Homo sapiens R-spondin-1 Proteins 0.000 description 3
- 101000825949 Homo sapiens R-spondin-2 Proteins 0.000 description 3
- 101000825960 Homo sapiens R-spondin-3 Proteins 0.000 description 3
- 101000825962 Homo sapiens R-spondin-4 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010066325 Keratin-17 Proteins 0.000 description 3
- 101710174256 Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 description 3
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 description 3
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
- 102100022762 R-spondin-1 Human genes 0.000 description 3
- 102100022763 R-spondin-2 Human genes 0.000 description 3
- 102100022766 R-spondin-3 Human genes 0.000 description 3
- 102100022759 R-spondin-4 Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010047118 Wnt Receptors Proteins 0.000 description 3
- 102000006757 Wnt Receptors Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 230000007646 directional migration Effects 0.000 description 3
- 108010007093 dispase Proteins 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 239000002657 fibrous material Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 3
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004966 intestinal stem cell Anatomy 0.000 description 3
- 210000003716 mesoderm Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000004626 scanning electron microscopy Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108700011013 transmembrane signaling receptor Proteins 0.000 description 3
- 102000057702 transmembrane signaling receptor Human genes 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 210000005167 vascular cell Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000952040 Homo sapiens Beta-defensin 1 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- -1 PDGF Proteins 0.000 description 2
- 208000006735 Periostitis Diseases 0.000 description 2
- 102100029337 Thyrotropin receptor Human genes 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003306 cell dissemination Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000010985 leather Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000000282 nail Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 210000003460 periosteum Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 108010023728 Alloderm Proteins 0.000 description 1
- 101000573149 Arabidopsis thaliana Pectinesterase 7 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100037437 Beta-defensin 1 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 101710178517 Defensin-5 Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108010060374 FSH Receptors Proteins 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102100027627 Follicle-stimulating hormone receptor Human genes 0.000 description 1
- 102000017357 Glycoprotein hormone receptor Human genes 0.000 description 1
- 108050005395 Glycoprotein hormone receptor Proteins 0.000 description 1
- 102000001895 Gonadotropin Receptors Human genes 0.000 description 1
- 108010040490 Gonadotropin Receptors Proteins 0.000 description 1
- 101000998027 Homo sapiens Keratin, type I cytoskeletal 17 Proteins 0.000 description 1
- 101100128138 Homo sapiens LGR6 gene Proteins 0.000 description 1
- 101000588130 Homo sapiens Microsomal triglyceride transfer protein large subunit Proteins 0.000 description 1
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 108010011942 LH Receptors Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100040788 Lutropin-choriogonadotropic hormone receptor Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 1
- 206010028665 Myxoedema Diseases 0.000 description 1
- WXOMTJVVIMOXJL-BOBFKVMVSA-A O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O WXOMTJVVIMOXJL-BOBFKVMVSA-A 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 206010048991 Ovarian adenoma Diseases 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 108090000253 Thyrotropin Receptors Proteins 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 102000052547 Wnt-1 Human genes 0.000 description 1
- 108700020987 Wnt-1 Proteins 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000000942 confocal micrograph Methods 0.000 description 1
- 210000000555 contractile cell Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000002514 epidermal stem cell Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000034756 hair follicle development Effects 0.000 description 1
- 230000009583 hair follicle growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 102000046975 human DEFB1 Human genes 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 208000003786 myxedema Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 201000009441 ovarian cystadenoma Diseases 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 210000003134 paneth cell Anatomy 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 210000001779 taste bud Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3813—Epithelial cells, e.g. keratinocytes, urothelial cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Developmental Biology & Embryology (AREA)
Description
本PCT国際特許出願は、2014年12月2日に出願された米国特許仮出願第62/086,526号の恩典を主張する2015年11月30日に出願された米国特許第14/954335号の優先権を主張する。これらは参照により本明細書に組み込まれる。
a)組織検体を得る工程;
b)該検体から最小限分極機能性単位含有LGR発現細胞を抽出する工程;
c)適切な供給源由来の皮下組織および皮下脂肪の細胞成分の加工処理を行う工程;
d)加工処理された皮下組織および皮下脂肪の該成分を、抽出された該最小限分極機能性単位に添加し、上皮幹細胞単一性(singularity)単位を作出する工程;
e)該上皮幹細胞単一性単位を富化させる工程;
f)該上皮幹細胞単一性単位を構築物のスカフォールドに添加する工程;ならびに
g)得られた組成物の最小限分極の維持を検証する工程
を特徴とする、最小限分極微細凝集塊多細胞組成物を作製するための方法を特徴とするものである。
本詳細説明において、「一実施形態(one embodiment,an embodiment)」または「実施形態において(in embodiments)」に対する言及は、言及されている特色が本発明の少なくとも1つの実施形態に含まれていることを意味する。さらに、「一実施形態(one embodiment,an embodiment)」または「実施形態(embodiments)」に対する個々の言及は、必ずしも同じ実施形態に言及しているのではない;しかしながら、その旨の記載がない限り、および当業者に容易に自明である場合を除き、これらはいずれも、互いに排他的な実施形態ではない。従って、本発明には、本明細書に記載の実施形態の任意のさまざまな組合せおよび/または統合が包含され得る。本明細書で用いている専門用語は、具体的な実施形態を説明する目的のためのものにすぎず、本発明の限定を意図するものではない。
以下は、本発明の一実施形態の実施のための実例のプロトコルシーケンスを示す一連の実施例である。
i.1部の冷却した10×培養培地の10×PBSを8部の冷却したコラーゲンベースの溶液に、静かにグルグル回しながらゆっくり添加する。ECMおよびバイアビリティタンパク質をこの懸濁液に添加する;
ii.滅菌した0.1M NaOHを使用し、pH調整を注意深くモニタリングしながら混合物のpHを7.2から7.6に調整する;
iii.最終容量を滅菌したモレキュラーグレードウォーター(molecular grade water)で総量10部に調整する;
iv.ゲル化を抑制するため、混合物の温度を2から10℃に維持する,
v.37℃までおよそ90から120分間昇温することによってゲルを形成させる;
vi.滅菌したマイクロニードルプレスでスカフォールドに孔をあける(必要であれば保存のために、スカフォールドにフリーズドライの方法を行ってもよい。)。
実施例1は、本発明の一実施形態による最小限分極機能性単位の抽出のための方法に関するものである。検体を得た後、これを関連輸送容器から取り出した後:
i.検体を、パルスレスキュー(pulse rescue)培地を含む滅菌した50ml容コニカルチューブ内に入れ、ロッカーに5分間入れ、新鮮培地と新たな容器で合計3回繰り返す;
ii.検体を取り出してパルス培地を含む滅菌した培養皿に入れ、脂肪および皮下要素を真皮コンパートメントおよび表皮コンパートメントから注意深く切除する。毛包単位は定位置に残し、過度に切開しない;
iii.切除した皮下脂肪成分を、PRMを含む別の50ml容コニカルチューブに入れ、低速ロッカーで+4℃に置く。
iv.残存皮膚要素を含む表皮コンパートメント、毛包コンパートメントおよび真皮コンパートメントを、超微細WECPREP(登録商標) Bladeまたは何らかの形態のマイクロ−16ランセットを用いて、最小限分極機能性単位(MPFU)にセクション化する;
v.MPFU成分を、パルス培地を含む別の50ml容コニカルチューブに入れ、+4℃に置く。
[実施例2]
実施例2は、皮下組織および皮下脂肪の細胞成分の加工処理に関するものである。実施例2において以下の工程を列挙する:
i.70%エタノール(EtOH)を組織容器の外側に噴霧し、この組織容器を層流キャビネット内に入れる;
ii.微生物学的試験のために組織試料を送るか、または培地を移す;
iii.事前に洗浄した脂肪および皮下組織を150mmの滅菌したペトリ皿に入れる;
iv.組織をPRMで2回洗浄する;
v.組織を、滅菌した外科用器具で小(3mm)片にトリミングし、パルス培地を含む滅菌した培養物保持皿に入れるとともにこの切除作業を終了する;
vi.保持皿から培地を吸引し、検体を、滅菌したスクープまたはピンセットで取り出した後、検体を、消化酵素の予備混合溶液(コラーゲナーゼとディスパーゼベース)であるMSC Enzymatic Digestive Mediaを含む50ml容コニカルチューブに入れ、これを、37℃の水浴中または乾熱低速振盪機内に入れ、30分間または残存する粒状物質がほとんどなくなるまで振盪する;
vii.37℃のリン酸緩衝生理食塩水(PBS)エチレンジアミン四酢酸(EDTA)(等容量のPBS−EDTA)を添加して消化を止める;
viii.懸濁液を10分間、遠心分離して「軟」ペレットを生成させる;
ix.上部の液体を廃棄し、滅菌したピペットを使用し、脂肪集団を保存塊の間質血管細胞群(SVF)から分離する;
x.2つの別々のコニカルチューブで、SVFをリン酸緩衝生理食塩水/EDTA,PBS−EDTA(1mMのEDTA)中に再懸濁させ、脂肪細胞集団をPRM中に再懸濁させる;
xi.100μmの滅菌フィルターを使用し、懸濁液を滅菌した新たなコニカルチューブに入れる;
xii.フィルターをPBS−EDTAで洗浄する;
xiiiv.懸濁液を室温で10分間スピン濾過した後、培地を吸引し、吸引した培地を既知容量の新鮮培地と交換する;
xiv.COUNTESS(登録商標)自動セルカウンター(Thermo Fisher Scientific)を使用し、細胞集団を計数してバイアビリティを測定する;
xv.得られた細胞集団の20%を、Thermo Fisher Scientific製のSYNTHA−FREEZE(登録商標) CTS(商標)(Cell Therapy Systems)での冷結保存のために取り出し、続いて、構築物のアセンブリのために残りの80%の集団を用いて適切にカタロギングする。
実施例3は、本発明の一実施形態による構築物の実施例への皮下組織および皮下脂肪成分の添加に関するものである。実例の成分添加の例は:
i.アセンブルされて洗浄されたスカフォールドを既に含んでいる滅菌したNUNC(登録商標)Skin Graft Cell Culture Dishまたは自動ディッシュを層流フードに入れ、スカフォールドを再度、パルス培地で2回洗浄した後、細胞を添加する;
ii.各培養槽に追跡番号のラベルを差し込む;
iii.およそ5×105から1×106個の混合SVF細胞/皿システムおよび1×105個の脂肪細胞/皿を移す;
iv.状況の具体的な要件に指示されるとおりに自己PRPを含む、または含まない完全培養培地をローディングレザーバに添加する;
v.皿を低速ロッカー上のインキュベータ内に1時間移した後、取り出し、別のセンチネルインキュベータ内に平らな状態で48時間静置する;
vi.48時間後に培養培地を洗浄し、非付着性細胞胞を廃棄し、完全培養培地を新しいものにする。細胞イメージングデバイス、例えば、EVOS(登録商標)(ThermoFisher Scientific)を用いてイメージングし、指定された追跡番号とともに保存する。
vii.72時間毎に培養培地を交換する;
viii.コンフルエンスになったら、培養物をダルベッコリン酸緩衝生理食塩水(DPBS)で洗浄し、培養培地を新鮮培地と交換する。
ix.上皮幹細胞機能性単一性構築物(ESC FSU)を直接、間葉幹細胞(MSC)構築物の表面上に置き、ESC培地を添加して両方の構築物を覆い、これらをイメージングし、構築物をインキュベータ内に戻す。
x.構築物の培地を48時間毎に変える/交換する
ことを含むものである。
実施例4は、最小限分極上皮幹細胞単一性単位の富化に関するものである。実施例1の後、MPFUを15ml容コニカルチューブ内のパルスレスキュー培地中に入れ、スピン/遠心分離して軟ペレットにする。次いで、この物質を以下の部分消化の過程に供する:
i.事前にアリコートに分けて凍結させた10mlの消化バッファー(コラーゲナーゼとディスパーゼベース)を入手する、これは、MPFUに添加する前に室温にしておく;
ii.この消化溶液をMPFUの軟ペレットに添加して穏やかに混合し、チューブを軽く叩くことによってMPFUを溶液全体に分布させる;
iii.このチューブを37℃の水浴中または乾燥インキュベータ内に10分間入れる;
iv.チューブを浴/インキュベータから取り出し、チューブを穏やかに軽く叩き、内容物を繊維状物について検査する;
v.繊維状物が観察されたら、内容物を遠心分離して軟ペレットにする;
vi.細胞ペレットを、5から10mLの既知組成ケラチノサイトSFM完全培地(ケラチノサイト−SFM(1×),ThermoFisher Scientific製)中で洗浄し、遠心分離して再度、軟ペレットにする;
vii.活性化された機能性単一性単位のペレットを5mLのケラチノサイト−SFM完全培地中に再懸濁させる;および
viii.該単位の細胞密度を、COUNTESS(登録商標)Automated Cell Counter(ThermoFisher Scientific)を用いて測定する。
実施例5は、実施例4で得られた上皮幹細胞機能性単一性体(ESC aFSU)を構築物/スカフォールドに添加することを含むものである。この手順には:
i.アセンブルされて洗浄されたスカフォールドを既に含んでいるUPCELL(商標) Surface Skin Graft Cell Culture Dishを配置し、生理学的pHを確実にするため、スカフォールドを再度、パルス培地で2回洗浄した後、細胞を添加する;
ii.各培養槽を唯一の追跡番号でラベル表示する;
iii.ESC aFSUを構築物に、使い捨てトランスファーピペットによって、既知組成ケラチノサイトSFM完全培地(自己PRPの添加は任意である。)を用いて移す;
iv.完全培養培地を、選択されたローディングレザーバに添加し、構築物の完全被覆を確実にする;
v.皿を、低速ロッカー上のインキュベータに1時間移す。次いで、ロッカーから取り出し、別のセンチネルインキュベータ内に48時間、平らな状態のままにしておく;
vi.48時間目、培養培地を吸引し、新鮮ケラチノサイトSFM培養培地を添加する。培養物をEVOS(登録商標)でイメージングし、培養物を指定された追跡番号とともに保存する。歯肉線維芽細胞(GF)集団およびバイアビリティタンパク質が増大する、および/またはこの時点で必要性が検出されればPRPを補給する。
vii.培養培地を48から72時間毎に交換する;
viii.コンフルエンスに達したら、培養物をDPBSで洗浄し、培地を交換する。温度ベースシステムを用いてESC構築物スカフォールディングの温度を下げ、皿からの放出を容易にする;
ix.ESCを直接、MSC構築物の表面上に配し、混合培地を添加し、両方の構築物を被覆する。構築物をイメージングし、これをインキュベータ内に戻し、構築物培地を48時間毎に交換する。
x.分極の維持を確認するため、構築物を毎日イメージングし、分極が48時間維持されていたことを確認した後、適切な角化(外皮形成)培地を添加する;
xi.構築物を収集時にパルス培地で2回洗浄し、培地を、CTS(商標)STEMPRO(登録商標)MSC SFMベースを用いた既知組成輸送培地と交換する
ことが包含される。
実施例6は、品質保証および構築物の仕上げ(冷結保存を伴う)のための実例のプロトコルを示す。これは、細胞療法適用のための基底の適正製造基準(GMP)に従う輸送のための構築物の調製を包含し:
i.適切な容量のSYNTH−A−FREEZE(登録商標)冷結保存培地(Thermo Fisher Scientific)を入手し、使用まで培地を2℃から8℃で保存する;
ii.細胞を調製し、収集し、密度をCOUNTESS(登録商標)Automated Cell Counterを用いて測定した後、所望の細胞量まで遠心分離する。この場合、SYNTH−A FREEZE(登録商標)培地での冷結保存に典型的な細胞密度は5×105から3×106である;
iii.細胞ペレットを、所定の容量の2℃から8℃のSYNTH−A−FREEZE(登録商標)培地中に再懸濁させる;
iv.即座に、得られた懸濁液のアリコートを冷結保存バイアル内に、製造業者の仕様書に従って分注する;
v.この冷結保存バイアルを、フリーザー温度を−80℃に維持する適切な冷結保存システム、例えば、MR.FROSTY(商標)システム(Thermo Fisher Scientific Inc.から入手可能)内に入れる;
vi.このバイアルを、−200℃から−125℃での液体窒素の長期気相保存に移す
ことを含むものである。
Claims (9)
- a)哺乳動物組織検体の真皮及び表皮から脂肪要素及び皮下要素の少なくとも一部を分離して、表皮コンパートメント、真皮コンパートメント、及び毛包コンパートメントを含む残存皮膚要素を提供するステップと、
b)前記残存皮膚要素をセクション化して、真皮セクション、表皮セクション、及び毛包セクションを含む細胞微細凝集塊を提供するステップと、
ここで、前記毛包セクションは、LGR4発現細胞、LGR5発現細胞、LGR6発現細胞、又はそれらの組み合わせから選択されるLGRを発現している生幹細胞を含み、前記真皮セクション、前記表皮セクション、及び前記毛包セクションの間の天然の組織は維持されており、
c)脂肪要素及び皮下要素を加工処理して間葉由来細胞集団を提供するステップと、
d)前記間葉由来細胞集団を前記細胞微細凝集塊に添加するステップと、
e)前記細胞微細凝集塊を富化させるステップと、
f)富化された前記細胞微細凝集塊を送達基材に添加して組成物を得るステップ
を含む方法により作成された組成物であって、
前記組成物は、移植を必要とする対象における損傷した組織部位に移植されたとき、表皮、真皮及び付属物を含む機能性の極性組織をアセンブルすることができる、組成物。 - 増殖因子をさらに含む、請求項1に記載の組成物。
- 遊走性/動員性の被検物をさらに含む、請求項1に記載の組成物。
- リガンドファミリー、R−スポンジン、上皮由来増殖因子(EDGF)、血小板由来増殖因子(PDGF)、Wntタンパク質、血管内皮増殖因子(VEGF)及び抗菌ペプチド又はその組み合わせからなる群より選択されるLGR特異的結合要素をさらに含む、請求項1〜3のいずれか一項に記載の組成物。
- 送達基材が、スカフォールディング、マトリックス、粒子、細胞、コラーゲン、繊維又はその組み合わせから選択される、請求項1に記載の組成物。
- 治療に使用するための、請求項1〜5のいずれか一項に記載の組成物。
- i)創傷の治療における使用、ここで、組成物は、前記創傷の治癒を早める、及び/又は、
ii)組織の治療における使用、ここで、組成物は、組織を治癒又は回復させる、及び/又は、
iii)組織領域、創傷、空隙、欠損組織又は血液のいずれか一の治療のための治療構築物としての使用、及び/又は、
iv)周囲の隣接組織の改変のための治療における治療構築物としての使用
のための、請求項1〜5のいずれか一項に記載の組成物。 - a)請求項1〜5のいずれか一項に記載の組成物と、
b)抗生物質又は抗かび剤から選択される少なくとも1つの薬剤と、
c)フィブリノゲンと
を含む組成物。 - フィブリノゲンが、ヒトフィブリノゲンであり、組成物が、ペニシリン、ストレプトマイシン、又はその組み合わせ、及びアムホテリシンBを含む、請求項8に記載の組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462086526P | 2014-12-02 | 2014-12-02 | |
US62/086,526 | 2014-12-02 | ||
US14/954,335 US10926001B2 (en) | 2014-12-02 | 2015-11-30 | Methods related to minimally polarized functional units |
US14/954,335 | 2015-11-30 | ||
PCT/US2015/063114 WO2016089825A1 (en) | 2014-12-02 | 2015-12-01 | Methods for development and use of minimally polarized function cell micro-aggregate units in tissue applications using lgr4, lgr5 and lgr6 expressing epithelial stem cells |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019004921A Division JP2019088299A (ja) | 2014-12-02 | 2019-01-16 | 組織適用におけるlgr4、lgr5およびlgr6発現上皮幹細胞を用いた最小限極性機能性細胞微細凝集塊単位の開発および使用のための方法 |
JP2020129610A Division JP2020182880A (ja) | 2014-12-02 | 2020-07-30 | 組織適用におけるlgr4、lgr5およびlgr6発現上皮幹細胞を用いた最小限極性機能性細胞微細凝集塊単位の開発および使用のための方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017538411A JP2017538411A (ja) | 2017-12-28 |
JP2017538411A5 JP2017538411A5 (ja) | 2018-07-05 |
JP6791854B2 true JP6791854B2 (ja) | 2020-11-25 |
Family
ID=56078499
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017530217A Active JP6791854B2 (ja) | 2014-12-02 | 2015-12-01 | 組織適用におけるlgr4、lgr5およびlgr6発現上皮幹細胞を用いた最小限分極機能性細胞微細凝集塊単位の開発および使用のための方法 |
JP2019004921A Pending JP2019088299A (ja) | 2014-12-02 | 2019-01-16 | 組織適用におけるlgr4、lgr5およびlgr6発現上皮幹細胞を用いた最小限極性機能性細胞微細凝集塊単位の開発および使用のための方法 |
JP2020129610A Pending JP2020182880A (ja) | 2014-12-02 | 2020-07-30 | 組織適用におけるlgr4、lgr5およびlgr6発現上皮幹細胞を用いた最小限極性機能性細胞微細凝集塊単位の開発および使用のための方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019004921A Pending JP2019088299A (ja) | 2014-12-02 | 2019-01-16 | 組織適用におけるlgr4、lgr5およびlgr6発現上皮幹細胞を用いた最小限極性機能性細胞微細凝集塊単位の開発および使用のための方法 |
JP2020129610A Pending JP2020182880A (ja) | 2014-12-02 | 2020-07-30 | 組織適用におけるlgr4、lgr5およびlgr6発現上皮幹細胞を用いた最小限極性機能性細胞微細凝集塊単位の開発および使用のための方法 |
Country Status (21)
Country | Link |
---|---|
US (7) | US10926001B2 (ja) |
EP (1) | EP3227431A4 (ja) |
JP (3) | JP6791854B2 (ja) |
KR (5) | KR20170098844A (ja) |
CN (1) | CN107250348B (ja) |
AU (3) | AU2015355187C1 (ja) |
BR (1) | BR112017011808A2 (ja) |
CA (1) | CA2969707C (ja) |
CO (1) | CO2017006640A2 (ja) |
CR (1) | CR20170296A (ja) |
EA (1) | EA201791125A1 (ja) |
GB (2) | GB2569056B (ja) |
HK (2) | HK1250515A1 (ja) |
IL (2) | IL252613B (ja) |
MX (2) | MX2017007243A (ja) |
MY (1) | MY184931A (ja) |
NZ (2) | NZ755260A (ja) |
PH (1) | PH12017501009B1 (ja) |
SG (2) | SG10201914058QA (ja) |
WO (1) | WO2016089825A1 (ja) |
ZA (1) | ZA201703907B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3088129A1 (en) * | 2018-01-26 | 2019-08-01 | Polarityte, Inc. | Composite-interfacing biomaterial accelerant substrate |
WO2019148143A1 (en) * | 2018-01-26 | 2019-08-01 | Polarityte, Inc. | Complex living interface-coordinated self-assembling materials (clicsam) |
FR3082123B1 (fr) | 2018-06-07 | 2020-10-16 | Urgo Rech Innovation Et Developpement | Pansement cellularise et son procede de fabrication |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040126881A1 (en) | 2002-09-06 | 2004-07-01 | Vincent Ronfard | Fibrin cell supports and methods of use thereof |
WO2006008009A2 (en) | 2004-07-23 | 2006-01-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with leucine-rich repeat-containing gpcr 6 (lgr6) |
US20060134074A1 (en) | 2004-08-30 | 2006-06-22 | Naughton Gail K | Compositions and methods for promoting hair growth |
WO2007048831A2 (en) | 2005-10-27 | 2007-05-03 | Coloplast A/S | Biodegradable scaffold with ecm material |
WO2008008009A1 (en) | 2006-07-13 | 2008-01-17 | St. Jude Medical Ab | Medical information management in a patient information hub system |
US8366723B2 (en) | 2006-08-03 | 2013-02-05 | Rassman Licensing, Llc | Hair harvesting device and method with localized subsurface dermal fluid insertion |
US7998737B2 (en) | 2006-09-12 | 2011-08-16 | Deutsches Krebsforschungszentrum | Cell culture of keratinocytes under non-differentiating conditions |
GB201111244D0 (en) | 2011-06-30 | 2011-08-17 | Konink Nl Akademie Van Wetenschappen Knaw | Culture media for stem cells |
EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
US9752124B2 (en) | 2009-02-03 | 2017-09-05 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising the stem cells |
FI20095355A0 (fi) | 2009-04-01 | 2009-04-01 | Helsingin Yliopisto | Regeneroituva aktiivinen matriisi ja sen käytöt |
JP2012531185A (ja) | 2009-06-25 | 2012-12-10 | 株式会社 資生堂 | Aff‐4を指標とした抗白髪剤のスクリーニング方法 |
US20110130711A1 (en) | 2009-11-19 | 2011-06-02 | Follica, Inc. | Hair growth treatment |
WO2012000180A1 (zh) | 2010-06-30 | 2012-01-05 | Chen Jinxi | 一种皮肤组织细胞聚合物的制备方法及其用途 |
GB201106395D0 (en) | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
EP2771454B1 (en) | 2011-10-27 | 2019-07-24 | Universität Leipzig | Method for deriving melanocytes from the hair follicle outer root sheath and preparation for grafting |
JP6186997B2 (ja) | 2012-08-07 | 2017-08-30 | 日油株式会社 | 塗布型帯電防止剤 |
US9655930B2 (en) | 2012-10-01 | 2017-05-23 | Aderans Research Institute, Inc. | Compositions and methods for producing reconstituted skin |
US20140106447A1 (en) | 2012-10-12 | 2014-04-17 | Mimedx Group, Inc. | Compositions and methods for recruiting stem cells |
KR102168088B1 (ko) | 2013-03-14 | 2020-10-20 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 상피 줄기 세포 확장 및 배양을 위한 조성물 및 방법 |
US9592257B2 (en) | 2013-10-11 | 2017-03-14 | MWV Cell, LLC | Complete human skin organ generated from culture-expanded cells |
CN103550828B (zh) * | 2013-10-17 | 2016-01-27 | 中国科学院动物研究所 | 一种基于毛囊干细胞和硅凝胶敷料的皮肤重建方法 |
TWI548413B (zh) | 2014-11-07 | 2016-09-11 | 國立臺灣大學 | 誘導毛囊新生的皮膚萃取物、組合物及其用途 |
-
2015
- 2015-11-30 US US14/954,335 patent/US10926001B2/en active Active
- 2015-12-01 CR CR20170296A patent/CR20170296A/es unknown
- 2015-12-01 AU AU2015355187A patent/AU2015355187C1/en active Active
- 2015-12-01 NZ NZ755260A patent/NZ755260A/en unknown
- 2015-12-01 KR KR1020177017887A patent/KR20170098844A/ko active Application Filing
- 2015-12-01 SG SG10201914058QA patent/SG10201914058QA/en unknown
- 2015-12-01 WO PCT/US2015/063114 patent/WO2016089825A1/en active Application Filing
- 2015-12-01 EP EP15865131.5A patent/EP3227431A4/en active Pending
- 2015-12-01 MY MYPI2017701990A patent/MY184931A/en unknown
- 2015-12-01 BR BR112017011808A patent/BR112017011808A2/pt not_active Application Discontinuation
- 2015-12-01 KR KR1020197028100A patent/KR20190111167A/ko not_active Application Discontinuation
- 2015-12-01 MX MX2017007243A patent/MX2017007243A/es unknown
- 2015-12-01 EA EA201791125A patent/EA201791125A1/ru unknown
- 2015-12-01 CN CN201580075326.3A patent/CN107250348B/zh active Active
- 2015-12-01 KR KR1020217010934A patent/KR20210043024A/ko not_active Application Discontinuation
- 2015-12-01 GB GB201902819A patent/GB2569056B/en active Active
- 2015-12-01 SG SG11201704502RA patent/SG11201704502RA/en unknown
- 2015-12-01 NZ NZ733433A patent/NZ733433A/en unknown
- 2015-12-01 JP JP2017530217A patent/JP6791854B2/ja active Active
- 2015-12-01 CA CA2969707A patent/CA2969707C/en active Active
- 2015-12-01 KR KR1020187036618A patent/KR20180136587A/ko not_active Application Discontinuation
- 2015-12-01 KR KR1020187036619A patent/KR20180136588A/ko not_active Application Discontinuation
- 2015-12-01 GB GB1710646.9A patent/GB2549872A/en not_active Withdrawn
-
2017
- 2017-05-31 PH PH12017501009A patent/PH12017501009B1/en unknown
- 2017-06-01 IL IL252613A patent/IL252613B/en unknown
- 2017-06-05 MX MX2023001655A patent/MX2023001655A/es unknown
- 2017-06-07 ZA ZA2017/03907A patent/ZA201703907B/en unknown
- 2017-06-30 CO CONC2017/0006640A patent/CO2017006640A2/es unknown
- 2017-07-14 US US15/650,656 patent/US20180154043A1/en not_active Abandoned
- 2017-07-14 US US15/650,659 patent/US11266765B2/en active Active
-
2018
- 2018-04-10 HK HK18104680.7A patent/HK1250515A1/zh unknown
- 2018-04-10 HK HK18104679.0A patent/HK1245327A1/zh unknown
- 2018-10-19 US US16/165,169 patent/US11000629B2/en active Active
-
2019
- 2019-01-16 JP JP2019004921A patent/JP2019088299A/ja active Pending
- 2019-10-02 AU AU2019240603A patent/AU2019240603B2/en active Active
-
2020
- 2020-07-30 JP JP2020129610A patent/JP2020182880A/ja active Pending
-
2021
- 2021-05-21 US US17/326,734 patent/US11338060B2/en active Active
- 2021-10-21 IL IL287488A patent/IL287488B2/en unknown
-
2022
- 2022-04-19 US US17/723,748 patent/US11596714B2/en active Active
-
2023
- 2023-02-03 US US18/164,308 patent/US20230181797A1/en active Pending
- 2023-05-08 AU AU2023202857A patent/AU2023202857A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Moshaverinia et al. | Application of stem cells derived from the periodontal ligament or gingival tissue sources for tendon tissue regeneration | |
Tian et al. | Myogenic differentiation of human bone marrow mesenchymal stem cells on a 3D nano fibrous scaffold for bladder tissue engineering | |
US11596714B2 (en) | Methods for development and use of minimally polarized function cell micro-aggregate units in tissue applications using LGR4, LGR5 and LGR6 expressing epithelial stem cells | |
Bellas et al. | Sustained volume retention in vivo with adipocyte and lipoaspirate seeded silk scaffolds | |
Sordi et al. | Three-dimensional bioactive hydrogel-based scaffolds for bone regeneration in implant dentistry | |
Papageorgiou et al. | Expanded skeletal stem and progenitor cells promote and participate in induced bone regeneration at subcritical BMP-2 dose | |
KR101885122B1 (ko) | 분화촉진 및 지속형 스페로이드 형태의 편도 유래 줄기세포의 배양 방법 | |
Yang et al. | Differentiated adipose‐derived stem cell cocultures for bone regeneration in RADA16‐I in vitro | |
CN103237885A (zh) | 用于细胞归巢和脂肪形成的组合物和方法 | |
JP2017538411A5 (ja) | ||
Day | Epithelial stem cells and tissue engineered intestine | |
Miao et al. | Osteogenic differentiation capacity of in vitro cultured human skeletal muscle for expedited bone tissue engineering | |
WO2017125159A1 (en) | Method for conditioning stem cells | |
Marshall et al. | In vitro and in vivo osteogenic differentiation of human adipose-derived stromal cells | |
OA19578A (en) | Methods for development and use of minimally polarized function cell microaggregate units in tissue applications using LGR4, LGR5 and LGR6 expressing epithelial stem cells | |
OA19580A (en) | Methods for development and use of minimally polarized function cell microaggregate units in tissue applications using LGR4, LGR5 and LGR6 expressing epithelial stem cells | |
JP6654323B2 (ja) | 重層上皮組織形成能を有する細胞、及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180518 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180627 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180717 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181015 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190116 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190402 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190626 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191001 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200331 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200730 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20200730 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200807 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20200811 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201027 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201105 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6791854 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |